Growth Metrics

Valion Bio (TIVC) Cash from Operations (2021 - 2025)

Valion Bio has reported Cash from Operations over the past 5 years, most recently at 2288000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 72.68% year-over-year to 2288000.0; the TTM value through Dec 2025 reached 7000000.0, down 22.27%, while the annual FY2025 figure was 7000000.0, 22.27% down from the prior year.
  • Cash from Operations for Q4 2025 was 2288000.0 at Valion Bio, down from 2012000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 543000.0 in Q2 2021 and troughed at 2772000.0 in Q3 2022.
  • A 5-year average of 1788350.0 and a median of 1792500.0 in 2023 define the central range for Cash from Operations.
  • Biggest five-year swings in Cash from Operations: tumbled 230.83% in 2022 and later soared 49.35% in 2024.
  • Year by year, Cash from Operations stood at 2760000.0 in 2021, then grew by 19.31% to 2227000.0 in 2022, then increased by 20.34% to 1774000.0 in 2023, then rose by 25.31% to 1325000.0 in 2024, then tumbled by 72.68% to 2288000.0 in 2025.
  • Business Quant data shows Cash from Operations for TIVC at 2288000.0 in Q4 2025, 2012000.0 in Q3 2025, and 1811000.0 in Q2 2025.